Seer, Inc. (NASDAQ:SEER) Sees Large Decline in Short Interest

Seer, Inc. (NASDAQ:SEER) was the target of a significant decrease in short interest in June. As of June 30th, there was short interest totalling 2,530,000 shares, a decrease of 13.7% from the June 15th total of 2,930,000 shares. Currently, 5.4% of the company’s stock are short sold. Based on an average daily volume of 613,700 shares, the days-to-cover ratio is currently 4.1 days.

Seer Stock Down 1.6 %

Shares of NASDAQ:SEER opened at $1.83 on Tuesday. The firm’s 50 day moving average price is $1.83 and its 200 day moving average price is $1.82. Seer has a fifty-two week low of $1.46 and a fifty-two week high of $5.65.

Seer (NASDAQ:SEER) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01). Seer had a negative return on equity of 20.69% and a negative net margin of 529.52%. The company had revenue of $3.07 million for the quarter, compared to analyst estimates of $3.55 million. Analysts expect that Seer will post -1.26 EPS for the current fiscal year.

Institutional Trading of Seer

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SEER. Deutsche Bank AG grew its position in shares of Seer by 27.3% during the third quarter. Deutsche Bank AG now owns 25,611 shares of the company’s stock worth $57,000 after acquiring an additional 5,485 shares during the last quarter. Acuitas Investments LLC purchased a new position in shares of Seer during the fourth quarter worth approximately $376,000. Syon Capital LLC purchased a new position in shares of Seer during the fourth quarter worth approximately $94,000. Marquette Asset Management LLC purchased a new position in shares of Seer during the fourth quarter worth approximately $96,000. Finally, Brandywine Managers LLC purchased a new position in shares of Seer during the fourth quarter worth approximately $86,000. Institutional investors and hedge funds own 75.20% of the company’s stock.

Seer Company Profile

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.